Ming-Lung Yu, MD, PhD
Kaohsiung Medical University
6
6
6
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+4 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Chang-Fu Chiu, MD
Paochien Hospital
Shared therapeutic areas:
Worked with same sponsors:
Chia-Yen Dai, MD, Ms
Kaohsiung Municipal Hsiao-Kang Hospital
Shared therapeutic areas:
Worked with same sponsors:
Jee-Fu Huang, MD
Foo Yin Hospital
Shared therapeutic areas:
Worked with same sponsors:
Jee-Fu Huang, MD
Kaohsiung Municipal Hsiao-Kang Hospital
Shared therapeutic areas:
Worked with same sponsors:
Tai-Chung Tseng, MD
Buddhist Xindian Tzu Chi General Hospital
Shared therapeutic areas:
Worked with same sponsors:
Pei-Jer Chen, MD, PhD
National Taiwan University Hospital
Shared therapeutic areas:
Worked with same sponsors:
Shih-Jer Hsu, MD
National Taiwan University Hospital, Yun-Lin Branch
Shared therapeutic areas:
Worked with same sponsors:
Cheng-Chao Liang, MD
Far Eastern Memorial Hospital
Shared therapeutic areas:
Worked with same sponsors:
Ching-Sheng Hsu, MD
Buddhist Xindian Tzu Chi General Hospital
Shared therapeutic areas:
Worked with same sponsors:
Chih-Lin Lin, MD
Taipei City Hospital, Ren-Ai Branch
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C
Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C
A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection
All 6 trials loaded